Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
TRIM67 antisense RNA 1 (TRIM67-AS1) is a long non-coding RNA (lncRNA) transcribed from the antisense strand of the TRIM67 gene region[5]. As an antisense RNA, it regulates the expression of its sense counterpart gene (TRIM67) at various levels—potentially affecting transcription, splicing, mRNA stability, or translation[3]. Antisense RNAs like TRIM67-AS1 may act either in cis (local effects on the same chromosome) or in trans (distant loci); their main function generally involves modulation of gene expression through RNA-RNA or chromatin-associated mechanisms[3]. While the protein-coding gene TRIM67 is implicated in cancer biology and neuronal differentiation, evidence specifically implicating TRIM67-AS1 itself as a direct therapeutic target or drug-interacting entity is lacking; its main role is as a regulatory non-coding RNA[3][5]. No approved therapies are known to specifically target TRIM67-AS1, and its primary relevance at present appears to be in molecular research and potentially as a disease biomarker in cancer.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on TRIM67 antisense RNA 1 (TRIM67-AS1).